Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy

Respir Med Case Rep. 2022 Nov 28:41:101785. doi: 10.1016/j.rmcr.2022.101785. eCollection 2023.


A 26-year-old female with steroid dependent eosinophilic asthma and nasal polyps who had successfully been treated with mepolizumab for 17 consecutive months with complete steroid withdrawal and symptoms control, stopped biologic treatment due to pregnancy efforts. Mepolizumab discontinuation resulted in frequent exacerbations and daily symptoms despite high dose ICS/LABA and re-initiation of oral steroids. Mepolizumab was initiated again, followed by improvement of asthma control and gradual withdrawal of steroids within 2 months. The patient became pregnant during the fourth month of mepolizumab re-initiation. The patient presented two asthma exacerbations during pregnancy treated with short course (3 days) oral steroids and delivery was uneventful (female, Apgar 9, weight 2750 g, length 59 cm) in week 40 by caesarean section.

Keywords: ACT, Asthma Control Score; Asthma; FEV1, Forced Expiratory Volume in 1 second; ICS, Inhaled Corticosteroids; LABA, Long-Acting Beta-Agonists; LAMA, Long-Acting Muscarinic Antagonists; Mepolizumab; OCS, Oral Corticosteroids; Pregnancy.

Publication types

  • Case Reports